Escitalopram is associated with reductions in pain severity and pain interference in opioid dependent patients with depressive symptoms

Abstract

Pain is common among opioid-dependent patients, yet pharmacologic strategies are limited. The aim of this study was to explore whether escitalopram, a selective serotonin reuptake inhibitor, was associated with reductions in pain. The study used longitudinal data from a randomized, controlled trial that evaluated the effects of escitalopram on treatment retention in patients with depressive symptoms who were initiating buprenorphine/naloxone for treatment of opioid dependence. Participants were randomized to receive escitalopram 10 mg or placebo daily. Changes in pain severity, pain interference, and depression were assessed at 1-, 2-, and 3-month visits with the visual analog scale, Brief Pain Inventory, and the Beck Depression Inventory II, respectively. Fixed-effects estimators for panel regression models were used to assess the effects of intervention on changes in outcomes over time. Additional models were estimated to explore whether the intervention effect was mediated by within-person changes in depression. In this sample of 147 adults, we found that participants randomized to escitalopram had significantly larger reductions on both pain severity (b=-14.34, t=-2.66, P<.01) and pain interference (b=-1.20, t=-2.23, P<.05) between baseline and follow-up. After adjusting for within-subject changes in depression, the estimated effects of escitalopram on pain severity and pain interference were virtually identical to the unadjusted effects. This study of opioid-dependent patients with depressive symptoms found that treatment with escitalopram was associated with clinically meaningful reductions in pain severity and pain interference during the first 3 months of therapy.

Trial registration: ClinicalTrials.gov NCT00475878.

Copyright © 2011 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.

Figures

Figure 1

Change in Pain Severity (VAS) and Pain Interference (BPI) Baseline to 3-Months. *Error bars denote 95% confidence interval estimates of the mean.

Figure 2

Predicted Follow-Up Mean VAS and BPI Scores by Intervention Group. * *Predicted values were estimated using the fixed-effects estimator (see Table 2 – Model 1); error bars denote 95% confidence interval estimates of the predicted mean.